Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression

In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen.

Access an interview with Dr Moti Ramgopal on the phase 3/3b FLAIR and ATLAS-2M pooled analysis – efficacy and safety outcomes through week 96 by race

Questions:

1. What are the unmet needs in the maintenance of HIV-1 virologic suppression? (0:08)

Disclosures: Moti Ramgopal is a consultant for Merck, ViiV, and Gilead; and is a speaker’s bureau participant with Abbvie, Gilead, ViiV, and Janssen.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022

Access more HIV content here